N/A N=34 Diagnostic

Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

Renal Cell Carcinoma · Kidney Cancer

Bottom Line

View on ClinicalTrials.gov: NCT02687139 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2020

Primary outcome: Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: 18F-DCFPyL (Drug); PET/CT (Procedure)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Johns Hopkins University
Primary completion: Apr 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC)	34	—
PRIMARY Number of Participants With a Correlation Between Radiotracer Uptake on 18F-DCFPyL PET/CT and Conventional Imaging	4	—

Summary

In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).

Eligibility Criteria

Inclusion Criteria

Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma
Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment

Exclusion Criteria

History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin)
Administered a radioisotope within 5 physical half-lives prior to study enrollment
Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center))
Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomography-computed tomography (PET/CT)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02687139). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.